Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).

Authors:
Lee BW; Min K; Hong EG; Ku BJ; Kang JG and 7 more

Journal:
Endocrinol Metab (Seoul)

Publication Year: 2023

DOI:
10.3803/EnM.2023.1688

PMCID:
PMC10323160

PMID:
37408283

Journal Information

Full Title: Endocrinol Metab (Seoul)

Abbreviation: Endocrinol Metab (Seoul)

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Endocrinology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST: This study was funded by LG Chem, Ltd. No potential conflict of interest relevant to this article was reported."

Evidence found in paper:

"CONFLICTS OF INTEREST: This study was funded by LG Chem, Ltd. No potential conflict of interest relevant to this article was reported."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025